JP7746157B2 - 膠芽腫の治療および予防 - Google Patents

膠芽腫の治療および予防

Info

Publication number
JP7746157B2
JP7746157B2 JP2021534294A JP2021534294A JP7746157B2 JP 7746157 B2 JP7746157 B2 JP 7746157B2 JP 2021534294 A JP2021534294 A JP 2021534294A JP 2021534294 A JP2021534294 A JP 2021534294A JP 7746157 B2 JP7746157 B2 JP 7746157B2
Authority
JP
Japan
Prior art keywords
selective
day
antagonist
use according
adrenergic receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021534294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517517A (ja
JP2022517517A5 (https=
Inventor
ホセ、マリア、サンチェス－プエレス、ゴンザレス－カルバハル
ルイサ、マリア、ボテッラ、キュベルズ
タニア、アグアド、サンチェス
アンヘル、クエスタ、マルチネス
ビルヒニア、アルビニャーナ、ディアス
カリーナ、ビジャル、ゴメス－デ、ラス、エラス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alianza Espanola De Familias De Von Hippel Lindau Vhl
Consejo Superior de Investigaciones Cientificas CSIC
Original Assignee
Alianza Espanola De Familias De Von Hippel Lindau Vhl
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alianza Espanola De Familias De Von Hippel Lindau Vhl, Consejo Superior de Investigaciones Cientificas CSIC filed Critical Alianza Espanola De Familias De Von Hippel Lindau Vhl
Publication of JP2022517517A publication Critical patent/JP2022517517A/ja
Publication of JP2022517517A5 publication Critical patent/JP2022517517A5/ja
Application granted granted Critical
Publication of JP7746157B2 publication Critical patent/JP7746157B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021534294A 2018-12-12 2019-12-12 膠芽腫の治療および予防 Active JP7746157B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382917.5A EP3666266A1 (en) 2018-12-12 2018-12-12 Treatment and prevention of glioblastoma
EP18382917.5 2018-12-12
PCT/EP2019/084822 WO2020120656A1 (en) 2018-12-12 2019-12-12 Treatment and prevention of glioblastoma

Publications (3)

Publication Number Publication Date
JP2022517517A JP2022517517A (ja) 2022-03-09
JP2022517517A5 JP2022517517A5 (https=) 2022-12-20
JP7746157B2 true JP7746157B2 (ja) 2025-09-30

Family

ID=64746483

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534294A Active JP7746157B2 (ja) 2018-12-12 2019-12-12 膠芽腫の治療および予防

Country Status (7)

Country Link
US (1) US20220008362A1 (https=)
EP (2) EP3666266A1 (https=)
JP (1) JP7746157B2 (https=)
CN (1) CN113365619A (https=)
CA (1) CA3122640A1 (https=)
ES (1) ES2986469T3 (https=)
WO (1) WO2020120656A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3048032A1 (es) * 2025-05-27 2025-12-05 Univ Madrid Complutense N-(4-Ariloxi-3-hidroxibutan-2-il)alcanamidas con actividad antagonista adrenérgica beta-2 selectiva

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015121500A1 (en) * 2014-02-17 2015-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for use in the treatment of ventilator-induced diaphragmatic dysfunction

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ICI 118551 hydrochloride, beta2 adrenoreceptor antagonist ab120808 ，2012年， ，https ://www.abcam.com/ici-118551-hydrochloride-beta-2-adrenoreceptor-antagonist? ab 120808. html#top-0
Molecular Pharmacology，1996年，Vol.49 No.5 ，p.927-937
Neuro Oncol，2016年，Vol.18 No.6，p.840-8，doi: 10.1093/neuonc/nov299.
Pharm Biol.，2014年，Vol.52 No.11，p.1374-1381

Also Published As

Publication number Publication date
EP3893861B1 (en) 2024-08-07
CN113365619A (zh) 2021-09-07
JP2022517517A (ja) 2022-03-09
EP3893861C0 (en) 2024-08-07
ES2986469T3 (es) 2024-11-11
US20220008362A1 (en) 2022-01-13
CA3122640A1 (en) 2020-06-18
WO2020120656A1 (en) 2020-06-18
EP3666266A1 (en) 2020-06-17
EP3893861A1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
CN102105151B (zh) Cdk抑制剂在治疗神经胶质瘤中的应用
US10426773B2 (en) Systems pharmacology for treating ocular disorders
KR20200098536A (ko) Dux4 발현과 관련된 질병의 치료를 위한 화합물
JP7166021B2 (ja) 癌の処置のためのドーパミンβ－ヒドロキシラーゼ（ＤＢＨ）阻害剤およびセロトニン受容体（５－ＨＴ）アンタゴニストの使用
ES2905360T3 (es) Composiciones y métodos para detectar, tratar y prevenir enfermedades y trastornos
JP2020523355A (ja) 肉腫を処置することへの使用のためのチノスタムスチン
US20190231735A1 (en) Methods for treating cancer
JP6483736B2 (ja) 癌の治療のためのキナーゼ阻害剤
JP7746157B2 (ja) 膠芽腫の治療および予防
TW201709905A (zh) 治療癌症之方法
JP6489517B2 (ja) ガン幹細胞に対する分化促進薬及び脳腫瘍治療薬
Sánchez-Puelles et al. Treatment and prevention of glioblastoma
US20250064775A1 (en) Selective elimination of senescent cells by ferroptosis induction
CN107921105A (zh) Il‑8抑制剂用于治疗某些泌尿疾病的用途
CA3072389C (en) Selective beta2-adrenergic receptor antagonist for treating von hippel-lindau disease
US11730707B2 (en) Compounds for treating von Hippel-Lindau disease
WO2010087107A1 (ja) メラノーマの転移抑制剤
JP2019026611A (ja) 腫瘍治療組成物
EA044366B1 (ru) Соединения для лечения болезни фон гиппеля-линдау
KR20200134519A (ko) Mg624를 유효성분으로 포함하는 뇌암의 예방 또는 치료용 약학적 조성물
TW201740927A (zh) 用於膠質母細胞瘤維持療法之鞘氨醇激酶抑制劑及神經醯胺
HK1153938B (en) Use of a cdk inhibitor for the treatment of glioma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240412

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250304

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250917

R150 Certificate of patent or registration of utility model

Ref document number: 7746157

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150